Phase 3
N=15
Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
FSGS
Bottom Line
View on ClinicalTrials.gov: NCT02683889 ↗Enrolled (actual)
15
Serious AEs
6.7%
Results posted
Mar 2026
Primary outcome: Primary: Rate of Recurrence of FSGS as Seen in Renal Transplant Biopsies Proteinuria — 14 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Acthar (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Colorado, Denver
- Primary completion
- Jun 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Rate of Recurrence of FSGS as Seen in Renal Transplant Biopsies Proteinuria |
14 | — |
| PRIMARY Rate of Recurrence of Proteinuria |
3 | — |
| SECONDARY Renal Function After Transplantation |
— | — |
Summary
This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.
Eligibility Criteria
Inclusion Criteria
- FSGS
- To receive either a live donor or deceased donor kidney transplant
Exclusion Criteria
- Not having FSGS
Data sourced from ClinicalTrials.gov (NCT02683889). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.